Trial of PTK787/ZK 222584 Plus Paclitaxel

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 26, 2006

Primary Completion Date

May 29, 2008

Study Completion Date

May 29, 2008

Conditions
Metastatic Non-hematologic Malignancies
Interventions
DRUG

PTK787/ZK 222584

Taken in tablet form daily

DRUG

paclitaxel

Given as a 3-hour infusion once every 21 days

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER